Clinical trials
CAR T Cell clinical trials
Below are recruiting car t cell clinical trials, each written for real people, not researchers. We’re tracking 698 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07338604RecruitingEarly Phase 1
UTAA07 cell therapy for relapsed CD7+ blood cancers
This trial tests a new cell therapy called UTAA07 for people with blood or lymph cancers that have returned or not responded to other treatments. It is designed for cancers that carry a specific marker called CD7, and aims to see if this therapy can help control the disease.
Suzhou, JiangsuAges 18 years+ - NCT07644403Enrolling by invitationPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Solid Tumors
This trial tests IMC001, a new type of immune cell therapy designed to fight advanced solid cancers that have stopped responding to standard treatments. The therapy uses your own immune cells engineered to recognize and attack cancer cells.
BeijingAges 18–75 - NCT06912152RecruitingPhase 1
Testing MT027 for advanced belly-lining cancers
This trial tests an experimental intraperitoneal therapy (MT027) for people whose advanced solid tumors have spread to the lining of the belly (peritoneum) and haven't responded to standard treatments. It aims to see if this new approach can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT05625594RecruitingPhase 1
Test brain-directed CAR T cells for CNS lymphoma
This Phase 1 study tests a new type of immune therapy (CAR T cells) placed directly into the fluid around the brain to treat central nervous system (CNS) lymphoma. It mainly looks at safety and how well the treatment can control the lymphoma when other CNS treatments have not worked.
Duarte, CaliforniaAges 18 years+ - NCT07103668RecruitingPhase 3
Study of a new drug for advanced stomach cancer after prior treatments
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
BeijingAges 18 years+ - NCT06701201Enrolling by invitation
Long-term follow-up for SynKIR CAR T cell patients
This study monitors participants who have received a SynKIR CAR T cell treatment in a past Verismo Therapeutics trial. It aims to track long-term health and safety outcomes over time.
Denver, ColoradoAges 18 years+ - NCT04433221RecruitingPhase 1/Phase 2
Combination immunotherapy for sarcoma patients
This trial tests a combination of immune cells targeting sarcoma tumors. It is for people with advanced or recurrent sarcoma who have not responded well to standard treatments.
Shenzhen, GuangdongAges 1–75 - NCT04637503RecruitingPhase 1/Phase 2
CAR-T therapy for neuroblastoma targeting three markers
This trial tests a personalized CAR-T cell therapy that targets three specific markers (GD2, PSMA, and CD276) on neuroblastoma cells. It is for patients whose cancer has come back or not responded to standard treatment.
Shenzhen, GuangzhouAges 1–65 - NCT05105152RecruitingPhase 1
CAR T cell therapy for kids with CD33 AML that came back
This Phase 1 study tests a type of lab-made immune cell therapy (CAR T cells) made from your T cells to treat AML that has relapsed or not responded, as long as the cancer shows a marker called CD33. The goal is to see if the treatment is safe and can help control AML after it returns or resists standard therapy.
Seattle, WashingtonAges Up to 30 years - NCT05155189RecruitingPhase 1
Armored CAR-T treatment for advanced liver cancer
This Phase 1 trial tests the safety and early signs of effectiveness of an “armored” CAR-T cell therapy (C-CAR031) for advanced hepatocellular carcinoma (liver cancer). It may help by teaching the body’s immune cells to better recognize and attack the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT05323201RecruitingPhase 1/Phase 2
B7H3 CAR-T therapy for advanced liver cancer
This trial tests an immune therapy made from your own blood cells (CAR-T) to treat advanced, unresectable liver cancer. It’s designed for people whose tumor has a specific marker called B7H3 and who meet blood, organ, and safety requirements.
Xuzhou, JiangsuAges 18–70 - NCT05546723RecruitingPhase 1
Study drug for multiple myeloma after several prior treatments
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
Cleveland, OhioAges 18 years+ - NCT05722418RecruitingPhase 1
CRISPR-edited CAR-T for harder-to-treat myeloma
This Phase 1 study tests a lab-made immune cell therapy (CAR-T) made from a donor, with a CRISPR edit, for multiple myeloma that has come back or not responded to treatment. It aims to find the safest way to give the treatment and see how well it can control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT05748197RecruitingPhase 1
Study of ADCLEC.syn1 for relapsed or resistant AML
This Phase 1 study tests ADCLEC.syn1, a new treatment made from a patient’s immune cells, in adults with relapsed or refractory acute myeloid leukemia (AML). The goal is to see how safe it is and how well it may work, especially after standard treatments have not helped.
Basking Ridge, New JerseyAges 18 years+ - NCT05807789Recruiting
Genetic testing during CAR-T treatment for adults
This study looks at a patient’s genetic (molecular) information while they receive CAR-T cell therapy. The goal is to better understand how different biological factors may affect CAR-T treatment.
Bologna, ItalyAges 18–70 - NCT05988216Recruiting
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new type of immune cell therapy (CAR-T cells) for people with lupus that has not responded well to standard treatments. It aims to reset the immune system to reduce lupus activity.
Hangzhou, ZhejiangAges 18–65 - NCT06056102RecruitingPhase 1
CAR-T cell therapy to help highly sensitized kidney transplant patients
This trial tests whether a special immune cell treatment (CAR-T cells) can lower the antibodies that make it very hard for you to receive a kidney transplant. If it works, you might become eligible for a transplant sooner.
Boston, MassachusettsAges 18–65 - NCT06101381RecruitingPhase 1/Phase 2
Car-T cell therapy for relapsed or refractory leukemia and lymphoma
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
Campinas, São PauloAges 3–70 - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06287528RecruitingPhase 1
CAR T‑cell therapy with IL‑18 for returning B‑cell leukemia
This trial tests a new type of CAR T‑cell therapy that also makes an immune‑boosting protein called IL‑18. It is for people with B‑cell acute lymphoblastic leukemia that has come back or not gone away after standard treatments.
Basking Ridge, New JerseyAges 17 years+ - NCT06297226RecruitingPhase 2
CAR T cell therapy for multiple myeloma
This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.
Birmingham, AlabamaAges 18 years+ - NCT06340750RecruitingPhase 1
BAFF CAR-T cells for lupus that hasn't improved with standard treatments
This trial tests a new type of cell therapy called BAFF CAR-T cells (LMY-920) for lupus that hasn't gotten better with standard treatments. It aims to see if these special immune cells can help calm the overactive immune system in lupus.
Columbus, OhioAges 18–65 - NCT06420063RecruitingPhase 1/Phase 2
Two-step CAR-T therapy for AML with CD33/CD123
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
Beijing, Beijing MunicipalityAges 6–90 - NCT06430736RecruitingPhase 2
Tocilizumab before or during CAR-T therapy
This study tests whether giving tocilizumab (a drug that calms inflammation) before CAR-T cell therapy helps prevent side effects. It compares using it ahead of time versus only when needed. You may be eligible if you are scheduled for CAR-T therapy for lymphoma, leukemia, or myeloma.
Bern, Canton of BernAges 18 years+
Hear when a new CAR T Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car t cell?
- Yes. Clin2 currently lists 698 recruiting car t cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car t cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car t cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.